{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:20:44Z","timestamp":1793053244701,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.clinthera.2011.10.027","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T08:54:00Z","timestamp":1323852840000},"page":"1853-1867","source":"Crossref","is-referenced-by-count":14,"title":["Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile"],"prefix":"10.1016","volume":"33","author":[{"given":"Emmanuel","family":"Stip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Zhornitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Moteshafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"L\u00e9tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Stikarovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Tourjman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.10.027_bib1","series-title":"Zeldox [product information]","year":"2010"},{"key":"10.1016\/j.clinthera.2011.10.027_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.jcp.0000084028.22282.f2","article-title":"Ziprasidone metabolism, aldehyde oxidase, and clinical implications","volume":"23","author":"Beedham","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2011.10.027_bib4","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2011.10.027_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2011.10.027_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2009.06.008","article-title":"Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia","volume":"113","author":"Edlinger","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2011.10.027_bib7","author":"Bartholow"},{"key":"10.1016\/j.clinthera.2011.10.027_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psychres.2006.02.006","article-title":"Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics","volume":"144","author":"Gianfrancesco","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.clinthera.2011.10.027_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v67n0208","article-title":"Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics","volume":"67","author":"Gianfrancesco","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib11","article-title":"Comprehensive Meta-Analysis: a Computer Program for Research Synthesis","author":"Borenstein","year":"1999"},{"key":"10.1016\/j.clinthera.2011.10.027_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2011.10.027_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-10-26","article-title":"Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone","volume":"10","author":"Johnsen","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2010.08040484","article-title":"Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)","volume":"168","author":"Strom","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"4 Pt 3","key":"10.1016\/j.clinthera.2011.10.027_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/15622970802269589","article-title":"Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial","volume":"10","author":"Lublin","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.10.027_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/j.1875-9114.1998.tb03820.x","article-title":"The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone","volume":"18","author":"Hamelin","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2011.10.027_bib19","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib20","first-page":"58","article-title":"The effect of food on the absorption of oral ziprasidone","volume":"40","author":"Miceli","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.clinthera.2011.10.027_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.08m04104","article-title":"The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial","volume":"70","author":"Gandelman","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02244926","article-title":"Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride","volume":"112","author":"Bench","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2011.10.027_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02245614","article-title":"The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography","volume":"124","author":"Bench","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2011.10.027_bib24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0b013e31818ba2f6","article-title":"Striatal and extrastriatal D2\/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2\/D3-receptor occupancy of ziprasidone)","volume":"28","author":"Vernaleken","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1592\/phco.30.2.127","article-title":"Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder","volume":"30","author":"Miceli","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2011.10.027_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2011.10.027_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2011.10.027_bib30","series-title":"Psychopharmacological Drugs Advisory Committee: Briefing Document for Zeldox Capsules (Ziprasidone HCI)","year":"2000"},{"key":"10.1016\/j.clinthera.2011.10.027_bib31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1017\/S1092852900023543","article-title":"Ziprasidone in black patients with schizophrenia: analysis of four short-term, double-blind studies","volume":"14","author":"Lawson","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2011.10.027_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2009.03.009","article-title":"Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials","volume":"111","author":"Citrome","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2011.10.027_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0269881108099418","article-title":"Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study","volume":"24","author":"Vieta","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib35","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4088\/JCP.v63n0609","article-title":"A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia","volume":"63","author":"Hirsch","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib36","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial","volume":"65","author":"Addington","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib37","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/appi.ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00213-004-2082-5","article-title":"Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study","volume":"178","author":"Brook","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2011.10.027_bib39","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.10.027_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib44","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145709000352","article-title":"Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol","volume":"12","author":"Potkin","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","article-title":"Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial","volume":"37","author":"Grootens","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.clinthera.2011.10.027_bib46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/01.jcp.0000132446.58348.40","article-title":"Comments on article by Harrigan et al: \u201cA randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.\u201d","volume":"24","author":"Jefferson","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib47","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1523\/JNEUROSCI.03-08-01607.1983","article-title":"Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons","volume":"3","author":"Chiodo","year":"1983","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2011.10.027_bib48","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2011.10.027_bib49","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e3283430a0e","article-title":"Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials","volume":"26","author":"Zhornitsky","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FTD.0b013e31818ac8ba","article-title":"Therapeutic drug monitoring of ziprasidone in a clinical treatment setting","volume":"30","author":"Cherm\u00e1","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2011.10.027_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eurpsy.2008.09.003","article-title":"The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey","volume":"24","author":"Vogel","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib53","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study","volume":"51","author":"Wessels","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/dmd.108.022814","article-title":"Receptor occupancy and brain free fraction","volume":"37","author":"Watson","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2011.10.027_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1472-8206.1999.tb00316.x","article-title":"Drug transfer across the blood-brain barrier and improvement of brain delivery","volume":"13","author":"Jolliet-Riant","year":"1999","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib56","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1476-5381.2009.00399.x","article-title":"Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure","volume":"158","author":"Gunasekaran","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib57","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1124\/jpet.105.092916","article-title":"Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain","volume":"316","author":"Summerfield","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.10.027_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pscychresns.2010.05.002","article-title":"Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function","volume":"183","author":"de Klerk","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.clinthera.2011.10.027_bib59","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2011.10.027_bib60","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib61","doi-asserted-by":"crossref","first-page":"PL103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2011.10.027_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(96)00218-7","article-title":"A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects","volume":"16","author":"Nyberg","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2011.10.027_bib63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-009-0107-y","article-title":"Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior","volume":"99","author":"Wu","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.10.027_bib65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0006-8993(02)02559-3","article-title":"The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor","volume":"939","author":"Xu","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2011.10.027_bib66","first-page":"863","article-title":"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans","volume":"25","author":"Prakash","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2011.10.027_bib67","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2011.10.027_bib68","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2011.10.027_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.10.027_bib70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.10.027_bib71","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1210\/en.2010-0519","article-title":"Beneficial metabolic effects caused by persistent activation of beta-cell M3 muscarinic acetylcholine receptors in transgenic mice","volume":"151","author":"Gautam","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2011.10.027_bib72","doi-asserted-by":"crossref","first-page":"21181","DOI":"10.1073\/pnas.1011651107","article-title":"M3-muscarinic receptor promotes insulin release via receptor phosphorylation\/arrestin-dependent activation of protein kinase D1","volume":"107","author":"Kong","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2011.10.027_bib73","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0022-3565(25)11335-9","article-title":"Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells","volume":"260","author":"Bolden","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.10.027_bib74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T19:03:20Z","timestamp":1742065400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811007168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0149291811007168"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.10.027","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}